LifeMap Solutions to participate in annual
Medidata Symposium, showcasing demo app that studies the effects of
caffeine consumption with attendees
LifeMap Solutions, the digital health subsidiary of BioTime,
Inc. (NYSE MKT: BTX), today announced a partnership with Medidata
(NASDAQ: MDSO), the leading provider of cloud-based solutions for
clinical research. LifeMap is joining Medidata’s AppConnect Partner
Program in support of mobile health (mHealth) innovation.
As a certified and inaugural AppConnect Partner, LifeMap
Solutions will leverage its extensive experience developing patient
engagement tools to build consumer-friendly mobile apps and remote
patient-research programs for clinical trials. These apps will
collect data from patients and upload it directly into the
regulatory-compliant, secure environment of the Medidata Clinical
CloudTM, making it easier for Medidata’s clients to bring mHealth
tools into the highly structured clinical trials environment.
“Medidata’s advanced technology has significantly impacted
clinical trials by making the process more efficient and
productive, much like how ResearchKit apps have impacted research
studies,” said Corey Bridges, CEO of LifeMap Solutions. “Through
this partnership, we’re expanding the scope of our professional
mHealth app development services. As the first commercial developer
on ResearchKit and one of the inaugural AppConnect Partners, we’re
excited to bring our skills to bear in the realm of clinical
trials.”
The AppConnect Partner Program will be unveiled at Medidata
Symposium, which runs from October 17-19, 2016, in Phoenix,
Arizona. Medidata’s annual conference brings together leaders from
across the life sciences to share innovative ideas and best
practices for the effective design, planning, execution, management
and reporting of clinical studies using the Medidata platform.
LifeMap Solutions will unveil Brewed Awakening, its mock
clinical trial app, at Medidata Symposium. Brewed Awakening studies
the effects of caffeine consumption on spatial memory. The mock app
aims to demonstrate the power and benefits of combining LifeMap’s
digital health expertise with Medidata’s powerful cloud platform. A
demo of the app will feature a short consent process for data
collection, followed by a series of tests and surveys that measure
spatial memory before and after caffeine consumption -- or with no
caffeine consumption at all. Dr. Steve Hershman, Principal
Scientist of LifeMap Solutions, will also participate in a panel
session on trends in, and best practices for, developing clinical
research apps and mHealth solutions.
“Through our AppConnect Partner Program, we are building an
ecosystem of world-class developers with powerful mobile
capabilities to support innovation and patient engagement in
clinical trials,” said Kara Dennis, Medidata’s managing director of
mHealth. “LifeMap has extensive experience building engaging,
consumer-friendly apps on ResearchKit for leading academic research
centers. We’re thrilled to partner with them and help our joint
clients adopt mobile health tools that have the potential to
increase the efficiency of their clinical development programs,
improve the experience for patients and speed up the delivery of
vital new therapies.”
About LifeMap Solutions
LifeMap Solutions develops innovative digital health solutions
with world-class medical, research, and commercial institutions.
From apps for research and clinical care to EMR-supporting
middleware and an app development platform, LifeMap's products
empower users to better understand and manage their health and
researchers and care providers to reach and serve larger audiences.
LifeMap Solutions is a subsidiary of BioTime, Inc., and is
headquartered in San Jose, California. For more information, please
visit www.lifemap-solutions.com.
About BioTime
BioTime, Inc. is a clinical-stage biotechnology company focused
on developing and commercializing novel therapies developed from
what we believe to be the world’s premier collection of pluripotent
stem cell assets. The foundation of our core therapeutic technology
platform is pluripotent stem cells that are capable of becoming any
of the cell types in the human body. Pluripotent stem cells have
potential application in many areas of medicine with large unmet
patient needs, including various age-related degenerative diseases
and degenerative conditions for which there presently are no cures.
Unlike pharmaceuticals that require a molecular target, therapeutic
strategies based on the use of pluripotent stem cells are generally
aimed at regenerating or replacing affected cells and tissues, and
therefore may have broader applicability than pharmaceutical
products.
Forward-Looking Statements
Statements pertaining to future financial and/or operating
results, future growth in research, technology, clinical
development, and potential opportunities for BioTime and its
subsidiaries, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management constitute forward-looking statements. Any statements
that are not historical fact (including, but not limited to
statements that contain words such as “will,” “believes,” “plans,”
“anticipates,” “expects,” “estimates”) should also be considered to
be forward-looking statements. Forward-looking statements involve
risks and uncertainties, including, without limitation, risks
inherent in the development and/or commercialization of potential
products, uncertainty in the results of clinical trials or
regulatory approvals, need and ability to obtain future capital,
and maintenance of intellectual property rights. Actual results may
differ materially from the results anticipated in these
forward-looking statements and as such should be evaluated together
with the many uncertainties that affect the business of BioTime and
its subsidiaries, particularly those mentioned in the cautionary
statements found in BioTime’s Securities and Exchange Commission
filings. BioTime disclaims any intent or obligation to update these
forward-looking statements.
About Medidata Patient Cloud
Medidata Patient Cloud® is a comprehensive and
regulatory-compliant mobile health solution that accelerates
patient-centric clinical research. Patient Cloud enables sponsors
to use sensors and apps that capture a richer, more complete
dataset directly from the patient, improving the clinical trial
experience on the Medidata Clinical Cloud. The suite of solutions
includes Sensor Link, a data ingestion platform for biosensors and
wearables; AppConnect, an SDK built to integrate apps within the
Medidata Clinical Cloud; and ePRo, a mobile app that collects
responses to patient questionnaires and diaries.
About Medidata
Medidata is reinventing global drug development by creating the
industry's leading cloud-based solutions for clinical research.
Through our advanced applications and intelligent data analytics,
Medidata helps advance the scientific goals of life sciences
customers worldwide, including more than 700 global pharmaceutical
companies, innovative biotech, diagnostic and device firms, leading
academic medical centers, and contract research organizations.
The Medidata Clinical Cloud® brings a new level of quality and
efficiency to clinical trials that empower our customers to make
more informed decisions earlier and faster. Our unparalleled
clinical trial data assets provide deep insights that pave the way
for future growth. The Medidata Clinical Cloud is the primary
technology solution powering clinical trials for 17 of the world's
top 25 global pharmaceutical companies, from study design and
planning through execution, management and reporting.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161018006511/en/
Media Relations ContactsTriplePoint for LifeMap
Solutions415-955-8500lifemap@triplepointpr.comorGotham
Communications, LLCBill Douglass,
646-504-0890bill@gothamcomm.com
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Sep 2023 to Sep 2024